In an effort to finally bring a diabetes drug to market – one that could complement its medical device and diagnostics businesses – Johnson & Johnson has filed a new drug application with FDA for canagliflozin, an SGLT-2 inhibitor that could be the first drug of its class to be approved.
Data presented on June 10 from five of its nine Phase III studies at the American Diabetes Association (ADA) meeting in Philadelphia demonstrated that the drug was able to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?